Avience Biomedicals Limited
Minimum investment
Bidding date
18 Jun - 22 Jun 2026
Price range
₹196 - ₹208
Minimum quantity
1,200
Minimum investment
₹1,17,600
Issue size
₹30 Cr.
IPO doc (link)
RHP docs
Listing exchange
NSE/BSE
Total Issue Size:
₹30 Crore
Fresh Issue: 97% (₹29 Cr)
OFS: 0% (₹0 Cr)
Fresh Issue – ₹29 Crore
Offer for Sale – ₹0 Crore
Before Issue: 87.89%
After Issue: 64.59%
Lock-in / Stabilization | Timeline |
|---|---|
Minimum Promoters' Contribution (20% of post-issue capital) | 3 Years from the date of allotment |
50% of promoter holding in excess of minimum contribution | 1 Year from the date of allotment |
Remaining 50% of promoter holding in excess of minimum contribution | 2 Years from the date of allotment |
Pre-IPO shares held by non-promoters | 1 Year from the date of allotment |
Note: Retail IPO investors have no lock-in and can sell shares from the listing day.
Founded in June 2024, Avience Biomedicals Limited is an ISO-certified healthcare company engaged in the manufacturing, supply, and export of molecular diagnostic solutions. The company operates in the biotechnology, genomics, and In-Vitro Diagnostics (IVD) industry, serving pathology laboratories, microbiology laboratories, hospitals, research centers, and government healthcare institutions across India and international markets. The company has evolved from manufacturing IVD rapid test kits to offering a diversified portfolio of diagnostic and medical products. Its product range includes rapid test kits, molecular diagnostic solutions, biochemistry analyzers, hematology analyzers, medical devices, reagents, and oxygen concentrators. Apart from manufacturing, the company also operates as a distributor and trader of medical equipment.
Avience Biomedicals operates its manufacturing facility in Noida, Uttar Pradesh, and focuses primarily on B2B and B2G business segments. As of January 31, 2026, the company had a workforce of 75 permanent employees and 33 contractual employees. The IPO proceeds will primarily be utilized for setting up a new manufacturing facility, funding working capital requirements, and supporting general corporate purposes.
Strong Product Portfolio: The company offers a comprehensive range of diagnostic products, analyzers, reagents, molecular testing kits, and medical devices catering to multiple healthcare segments.
Growing Presence in Healthcare Diagnostics: Increasing demand for diagnostic testing and healthcare infrastructure development can provide long-term growth opportunities.
ISO-Certified Operations: The company follows stringent quality control standards and complies with relevant regulatory requirements, enhancing customer confidence.
Expansion-Oriented IPO Utilization: Funds raised through the IPO will be invested in capacity expansion and working capital, which can support future business growth.
Established Distribution Network: The company has built a strong distribution network across India and is gradually expanding into international markets.
High Dependence on Healthcare Sector Demand: Any slowdown in diagnostic testing demand, changes in healthcare spending, or regulatory restrictions could impact business performance.
Relatively Young Corporate History: Although the promoters possess industry experience, the company itself was incorporated in 2024, resulting in a limited operating history as a listed entity.
Debt on Balance Sheet: The company reported total borrowings of Rs. 17.17 Crore as of January 31, 2026. Higher debt obligations may impact future profitability and cash flows.
Competitive Industry: The diagnostics and medical devices market is highly competitive, with established domestic and international players competing on technology, pricing, and distribution.
Margin Pressure Risk: Changes in raw material costs, import dependence, or pricing pressure from competitors may affect operating margins.
28.85 Cr.
Jan'26
4.18 Cr.
Jan'26
7.1 Cr.
Jan'26
57 investors voted
Active IPOs | |
|---|---|
Company name | Bid starts |
Turtlemint Fintech Solutions | 19-06-2026 |
Advit Jewels | 23-06-2026 |
Clay Craft India | 17-06-2026 |
Avience Biomedicals | 18-06-2026 |
